Company Filing History:
Years Active: 2018
Title: **Innovator Spotlight: Steffen Müller**
Introduction
Steffen Müller is a prolific inventor based in Essen, Germany, recognized for his contributions to the field of medicinal chemistry. He holds a significant patent that focuses on novel compounds important for the treatment of various diseases. His work exemplifies the innovative spirit necessary for advancements in pharmacology.
Latest Patents
Müller’s patent, titled "Substituted pyridobenzodiazepinone-derivatives and use thereof," centers on a class of compounds known as (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives. This innovation addresses the need for effective treatments for angiogenic disorders and hyperproliferative disorders where neovascularization is a significant concern. Specifically, the compounds related to this patent show promise in treating ophthalmological disorders, cancers, and tumors. The application outlines methods for preparing these derivatives and their utilization as monotherapy or in combination with other therapeutic measures.
Career Highlights
Steffen Müller is currently employed at Bayer Pharma Aktiengesellschaft, a leading global pharmaceutical company. His role has placed him at the forefront of research and development in innovative drug therapies. With only one patent to his name thus far, it is evident that his work is still in its early stages — a sign of the potential for future contributions to the field.
Collaborations
In his professional journey, Müller collaborates closely with notable colleagues such as Andreas Schall and Jürgen Klar. Their teamwork fosters an environment of creativity and shared innovation, enabling them to push the boundaries of pharmaceutical science together. Such partnerships are vital for the successful development of new treatment options.
Conclusion
Steffen Müller’s dedication to innovation and his groundbreaking patent represent significant strides in treating complex medical conditions. As he continues to work within Bayer Pharma Aktiengesellschaft and collaborates with talented peers, the medical community eagerly anticipates the future advancements that will emerge from his research endeavors.